IBM and Moderna have announced plans to collaborate to conduct a pilot of open technology-based approaches to improve visibility into the COVID-19 vaccine supply chain and monitor vaccine administration in real time.
IBM said Thursday initial work will focus on vaccine management platforms designed to prevent disruptions to the vaccine supply chain by enabling governments and health care providers to share data on individual batches of COVID-19 vaccines as they move from production facilities to administration sites.
"As governments, pharmacy chains, healthcare providers and life sciences companies continue to scale and connect their tools, and as new players enter the supply chain, open technology can help drive more transparency and bolster trust, while helping to ensure accessibility and equity in the process,“ said Jason Kelley, managing partner and global strategic alliances leader for IBM.
The companies will also explore the use of Digital Health Pass in addressing the pandemic. The blockchain technology-based pass could help organizations verify vaccination records, test results and other health credentials of employees, travelers and customers while allowing individuals to control how they share their personal health data.
Moderna and IBM will also study the use of artificial intelligence, hybrid cloud and other technologies in support of COVID-19 vaccine management efforts.
The Potomac Officers Club will hold its 3rd Annual Artificial Intelligence Summit on March 30 to foster discussions on how to advance AI technology at speed and how private-public partnerships are key to maintaining the competitive advantage within the tech race. To register for this virtual summit and view other upcoming events, visit the Potomac Officers Club Events page.